2014 Fiscal Year Final Research Report
Development of trifunctional antibodies in multiple myeloma
| Project/Area Number |
24591402
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Hematology
|
|---|
| Research Institution | The University of Tokyo |
|---|
Principal Investigator |
YASUI Hiroshi 東京大学, 医科学研究所, 特任講師 (40448593)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
ISHIDA Tadao 札幌医科大学, 医学部, 准教授 (20305220)
|
|---|
| Project Period (FY) |
2012-04-01 – 2015-03-31
|
| Keywords | 多発性骨髄腫 / 抗体医薬 / 橋渡し研究 / 三重特異性抗体 / がん免疫療法 |
|---|
| Outline of Final Research Achievements |
The trifunctional antibody can bind specifically to tumor antigens and the T-cell antigen CD3 via each of the Fab-fragments as well as to macrophages via its Fc-fragment. We have developed a trifunctional antibody, which binds to CD3 and antigen A expressed on the surface of multiple myeloma cells. Such binding results in antibody-dependent cell-mediated cytotoxicity against myeloma cells as well as antitumor activity in human myeloma mouse model. We plan on acquiring the intellectual property rights as well as the university-industry research collaboration in order to put this finding to the practical use as an anti-myeloma drug.
|
| Free Research Field |
血液学、腫瘍学
|
